{
    "id": 25294,
    "fullName": "BCL2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BCL2 positive indicates the presence of the BCL2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 596,
        "geneSymbol": "BCL2",
        "terms": [
            "BCL2",
            "Bcl-2",
            "PPP1R50"
        ]
    },
    "variant": "positive",
    "createDate": "08/30/2016",
    "updateDate": "05/15/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BDA-366 decreased viability BCL2-expressing small cell lung cancer cell lines in culture, with cell lines expressing higher levels of BCL2 demonstrating increased sensitivity (PMID: 26004684).",
            "molecularProfile": {
                "id": 26142,
                "profileName": "BCL2 positive"
            },
            "therapy": {
                "id": 3275,
                "therapyName": "BDA-366",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4086,
                    "pubMedId": 26004684,
                    "title": "Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26004684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cell lines highly expressing Bcl2 demonstrated sensitivity to Venclexta (venetoclax) in culture, resulting in inhibition of cell growth (Blood 2016 128:5104).",
            "molecularProfile": {
                "id": 26142,
                "profileName": "BCL2 positive"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7727,
                    "pubMedId": null,
                    "title": "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines",
                    "url": "http://www.bloodjournal.org/content/128/22/5104?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8047,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BDA-366 decreased viability BCL2-expressing non-small cell lung cancer cell lines in culture, with cell lines expressing higher levels of BCL2 demonstrating increased sensitivity, and induced apoptosis and inhibited tumor growth in cell line xenograft models (PMID: 26004684).",
            "molecularProfile": {
                "id": 26142,
                "profileName": "BCL2 positive"
            },
            "therapy": {
                "id": 3275,
                "therapyName": "BDA-366",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4086,
                    "pubMedId": 26004684,
                    "title": "Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26004684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8052,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BDA-366 and Afinitor (everolimus) worked synergistically to inhibit growth of a BCL2-expressing non-small cell lung cancer (NSCLC) cell line in culture and to induce tumor regression in cell line NSCLC xenograft models, with increased efficacy over either agent alone (PMID: 26004684).",
            "molecularProfile": {
                "id": 26142,
                "profileName": "BCL2 positive"
            },
            "therapy": {
                "id": 4627,
                "therapyName": "BDA-366 + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4086,
                    "pubMedId": 26004684,
                    "title": "Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26004684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8173,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with JQ1 resulted in decreased expression of BCL2 and BCL2L1 in murine transgenic lymphoma cells over expressing MYC, subsequently leading to increased expression of BCL2L11 (Bim) and apoptotic activity in culture (PMID: 27406984).",
            "molecularProfile": {
                "id": 26187,
                "profileName": "BCL2 pos BCL2L1 pos BCL2L11 pos MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8182,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, murine transgenic lymphoma cells over expressing MYC in culture demonstrated resistance to treatment with JQ1 due to a BCL2L11 (Bim)-null background (PMID: 27406984).",
            "molecularProfile": {
                "id": 26191,
                "profileName": "BCL2 pos BCL2L1 pos BCL2L11 neg MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8239,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Daunorubicin combination treatment reduced Bcl2 and Mcl1 association with Bcl2l11 (Bim), resulted in enhanced cytotoxicity in acute myeloid leukemia cells in culture (PMID: 27103402).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4669,
                "therapyName": "Daunorubicin + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6583,
                    "pubMedId": 27103402,
                    "title": "Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103402"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19075,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VU661013 and Venclexta (venetoclax) combination therapy reduced tumor burden and increased survival (p=0.003) in cell line xenograft models of MCL1 and BCL2-positive acute myeloid leukemia, and led to growth inhibition of a Venclexta (venetoclax)-resistant cell line and synergistic effects against VU661013-resistant cells in culture (PMID: 30185627).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 8905,
                "therapyName": "Venetoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9058,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute lymphocytic leukemia cells dependent with low Bcl2/Mcl1 ratio demonstrated minimal sensitivity to Venclexta (venetoclax) in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19074,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) treatment inhibited growth of a BCL2 and MCL1-positive acute myeloid leukemia cell line resistant to VU661013 in culture (PMID: 30185627).",
            "molecularProfile": {
                "id": 26205,
                "profileName": "BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8335,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 E255K and T315I in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26231,
                "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8336,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 E255V and T315I in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26232,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8338,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia (CML) patients harboring BCR-ABL1 and expressing Bcl2 in culture, and inhibited tumor growth in Bcl2 positive, BCR-ABL1-driven animal models of CML (PMID: 27605552).",
            "molecularProfile": {
                "id": 26233,
                "profileName": "BCR - ABL1 BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8337,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 H396R in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26234,
                "profileName": "BCR - ABL1 ABL1 H396R BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9070,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Iclusig (ponatinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4869,
                "therapyName": "Ponatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9071,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Sprycel (dasatinib) synergistically inhibited growth and induced apoptosis in patient-derived, Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture, resulted in tumor inhibition in patient-derived xenograft models (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4868,
                "therapyName": "Dasatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9066,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) inhibited growth and induced apoptosis in both patient-derived and established Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9069,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Gleevec (imatinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4867,
                "therapyName": "Imatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16417,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Nolvadex (tamoxifen) and Venclexta (venetoclax) combination treatment resulted in an objective response rate of 45% (15/33, 1 complete response, 14 partial response) and a clinical benefit rate of 70% (23/33) in patients with ER, BCL2-positive, ERBB2 (HER2)-nonamplified (negative) metastatic breast cancer, with a median duration of response of 42 weeks (PMID: 30518523).",
            "molecularProfile": {
                "id": 31628,
                "profileName": "BCL2 pos ESR1 pos"
            },
            "therapy": {
                "id": 8024,
                "therapyName": "Tamoxifen + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14490,
                    "pubMedId": 30518523,
                    "title": "A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518523"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19077,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and VU661013 combination therapy induced apoptosis and synergistically reduced tumor burden in a patient-derived xenograft (PDX) model of BCL2-positive and MCL1-dependent disseminated acute myeloid leukemia compared to Venclexta (venetoclax) treatment (PMID: 30185627).",
            "molecularProfile": {
                "id": 33895,
                "profileName": "BCL2 pos MCL1 over exp"
            },
            "therapy": {
                "id": 8905,
                "therapyName": "Venetoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20153,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VU661013 and Navitoclax (ABT-263) combination treatment induced apoptosis and inhibited growth of estrogen receptor-positive breast cancer cell lines expressing BCL2, BCL2L1, and MCL1 in culture, and induced cell death and inhibited tumor growth in a cell line xenograft model (PMID: 31595181).",
            "molecularProfile": {
                "id": 34907,
                "profileName": "BCL2 pos BCL2L1 pos MCL1 pos"
            },
            "therapy": {
                "id": 9280,
                "therapyName": "Navitoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16725,
                    "pubMedId": 31595181,
                    "title": "Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31595181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20151,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Navitoclax (ABT-263) combination treatment induced apoptosis and inhibited growth of estrogen receptor-positive breast cancer cell lines expressing BCL2 and BCL2L1 in culture, and inhibited mTORC1 signaling and tumor growth, and induced cell death in a cell line xenograft model (PMID: 31595181).",
            "molecularProfile": {
                "id": 34908,
                "profileName": "BCL2 pos BCL2L1 pos"
            },
            "therapy": {
                "id": 9279,
                "therapyName": "Everolimus + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16725,
                    "pubMedId": 31595181,
                    "title": "Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31595181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26142,
            "profileName": "BCL2 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26187,
            "profileName": "BCL2 pos BCL2L1 pos BCL2L11 pos MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26191,
            "profileName": "BCL2 pos BCL2L1 pos BCL2L11 neg MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26205,
            "profileName": "BCL2 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26231,
            "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26232,
            "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26233,
            "profileName": "BCR - ABL1 BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26234,
            "profileName": "BCR - ABL1 ABL1 H396R BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26700,
            "profileName": "BCR - ABL1 BCL2 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31628,
            "profileName": "BCL2 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33895,
            "profileName": "BCL2 pos MCL1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34508,
            "profileName": "BCL2 pos FLT3 exon 14 ins",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34509,
            "profileName": "BCL2 pos FLT3 exon 14 ins MCL1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34511,
            "profileName": "BCL2 pos FLT3 exon 14 ins MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34512,
            "profileName": "AKT1 pos AKT2 pos BCL2 pos FLT3 exon 14 ins",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34907,
            "profileName": "BCL2 pos BCL2L1 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34908,
            "profileName": "BCL2 pos BCL2L1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}